Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMed

Advancements in Promoting Angiogenesis in Tissue-Engineered Grafts in Various Organs: A Comprehensive Review.

Zare Jalise S., Brouki Milan P., Kialashaki E., Ghane M., Habibi S., Mehrabi A.

Narrative Review on Cardiovascular Disease, Immune Modulation, published in Macromol Biosci (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Macromol Biosci (2026)
Country
Germany
Reported sample size
—
Source database
PubMed
PMID
41840992
DOI
10.1002/mabi.202500453

Abstract (original English)

Vascularization remains a fundamental challenge in tissue engineering, directly impacting the survival, integration, and function of engineered grafts across diverse organ systems. This comprehensive review explores the latest advancements in promoting angiogenesis within tissue-engineered constructs, focusing on strategies that emulate natural vascular development to overcome ischemic limitations post-implantation. We examine three core domains of pro-angiogenic intervention: controlled delivery of growth factors (e.g., VEGF, FGF, PDGF), development of bioactive and mechanically tuned biomaterials (such as collagen, gelatin, hyaluronic acid, and decellularized matrices), and cell-based approaches leveraging stem and progenitor cells, including embryonic stem cells, induced pluripotent stem cells, and mesenchymal stem cells. Novel technologies such as 3D bioprinting, nanofabrication, and the use of extracellular vesicles have further enabled spatial and temporal control over vascular network formation. Organ-specific applications in cardiac, hepatic, dermal, osseous, pancreatic, musculoskeletal, adipose, and corneal tissues illustrate the translational potential of these techniques, while also highlighting the unique vascular requirements of each tissue type. Additionally, unconventional angiogenic inducers, such as parasite-derived proteins, are emerging as potential therapeut

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansTissue EngineeringNeovascularization, PhysiologicAnimalsAngiogenesisBiocompatible MaterialsDecellularized Extracellular Matrix

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research